Oral contraceptive use and salivary C-erbB-2, CEA and CA15-3 in healthy women: A case-control study

Medicina Oral, Patologia Oral y Cirugia Bucal

Volumn 16, Issue 1, 2011, Pages

  Vahedi, Mohammad ^a   Abdollahzadeh, Shermin ^a,c   Vaziri, Pejman Bakianian ^b   Mortazavi, Hamed ^a  

^a HAMADAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c NONE   (Iran)

Author keywords

Breast cancer; C erb B 2; CA 15 3; CEA; Oral contraceptive; Saliva

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADULT; ARTICLE; BODY MASS; BREAST FEEDING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PROTEIN EXPRESSION; SALIVA; STUDENT T TEST;

ADULT; CARCINOEMBRYONIC ANTIGEN; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; FEMALE; HUMANS; MIDDLE AGED; MUCIN-1; RECEPTOR, ERBB-2; SALIVA; YOUNG ADULT;

EID: 78751659917     PISSN: 16984447     EISSN: 16986946     Source Type: Journal    
DOI: 10.4317/medoral.16.e29     Document Type: Article

References (20)

1. Westhoff CL, Heartwell S, Edwards S, Zieman M, Stuart G, Cwiak C, et al. Oral contraceptive discontinuation: do side effects matter? Am J Obstet Gynecol. 2007;196:412.e1-6.
2. McIntyre R, Bigler L, Dellinger T, Pfeifer M, Mannery T, Streckfus C. Oral contraceptive usage and the expression of CA 15-3 and c-erbB-2 in the saliva of healthy women. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999;88:687-90.
3. Biglia N, Mariani L, Sgro L, Mininanni P, Moggio G, Sismondi P. Increased incidence of lobular breast cancer in women treated with hormone replacement therapy: implications for diagnosis, surgical and medical treatment. Endocr Relat Cancer. 2007;14:549-67. (Pubitemid 350074047)
4. Lester J. Breast cancer in 2007: incidence, risk assessment, and risk reduction strategies. Clin J Oncol Nurs. 2007;11:619-22.
5. Emekli-Alturfan E, Demir G, Kasikci E, Tunali-Akbay T, Pisiriciler R, Caliskan E, et al. Altered biochemical parameters in the saliva of patients with breast cancer. Tohoku J Exp Med. 2008;214:89-96. (Pubitemid 351513540)
6. Ross JS, Fletcher JA. The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. Oncologist. 1998;3:237-52.
7. Streckfus CF, Bigler L, Dellinger T, Kuhn M, Chouinard N, Dai X. The expression of the c-erbB-2 receptor protein in glandular salivary secretions. J Oral Pathol Med. 2004;33:595-600.
8. Streckfus C, Bigler L, Dellinger T, Dai X, Cox WJ, McArthur A, et al. Reliability assessment of soluble c-erbB-2 concentrations in the saliva of healthy women and men. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;91:174-9.
9. Agha-Hosseini F, Mirzaii-Dizgah I, Rahimi A. Correlation of serum and salivary CA15-3 levels in patients with breast cancer. Med Oral Patol Oral Cir Bucal. 2009;14:e521-4.
10. Guadagni F, Ferroni P, Carlini S, Mariotti S, Spila A, Aloe S, et al. A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal study. Clin Cancer Res. 2001;7:2357-62.
11. Streckfus C, Bigler L, Dellinger T, Pfeifer M, Rose A, Thigpen JT. CA 15-3 and c-erbB-2 presence in the saliva of women. Clin Oral Investig. 1999;3:138-43.
12. Navazesh M; ADA Council on Scientific Affairs and Division of Science. How can oral health care providers determine if patients have dry mouth? J Am Dent Assoc. 2003;134:613-20.
13. Dumeaux V, Fournier A, Lund E, Clavel-Chapelon F. Previous oral contraceptive use and breast cancer risk according to hormone replacement therapy use among postmenopausal women. Cancer Causes Control. 2005;16:537-44.
14. Kahlenborn C, Modugno F, Potter DM, Severs WB. Oral contraceptive use as a risk factor for premenopausal breast cancer: a metaanalysis. Mayo Clin Proc. 2006;81:1290-302.
15. Hankinson SE, Colditz GA, Willett WC. Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res. 2004;6:213-8.
16. Molina R, Filella X, Zanon G, Pahisa J, Alicarte J, Munoz M, et al. Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer. Anticancer Res. 2003;23:1043-50. (Pubitemid 36750917)
17. Molina R, Jo J, Filella X, Zanón G, Farrus B, Muñoz M, et al. CerbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients. Anticancer Res. 1999;19:2551-5.
18. Molina R, Jo J, Filella X, Zanon G, Pahisa J, Munoz M, et al. C-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Res Treat. 1998;51:109-19.
19. Schipper RG, Silletti E, Vingerhoeds MH. Saliva as research material: biochemical, physicochemical and practical aspects. Arch Oral Biol. 2007;52:1114-35.
20. Nieuw Amerongen AV, Ligtenberg AJ, Veerman EC. Implications for diagnostics in the biochemistry and physiology of saliva. Ann N Y Acad Sci. 2007;1098:1-6.